Follow Up of Patients Chronic Hepatitis B (CHB) Treated With Sebivo Using the 13C Methacetin Breath Test

Exclusion Criteria

• •1. History of hypersensitivity to any of the study drugs (Methacetin, Sebivo) or to drugs with similar chemical structures, including allergy to paracetamol.
• •2. Patient is pregnant or breastfeeding.
• •3. Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means. The exception of the aforementioned criteria will be given if they meet the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/ml (IU/L) or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy or have been surgically sterilized (e.g., bilateral tubal ligation) or the patient must agree to use two methods of birth control. This is any combination of hormonal contraception (implantable, patch, oral or injection), IUD, male or female condom with spermicidal gel, diaphragm, sponge or cervical cap. Women of childbearing potential must have a negative serum betahuman chorionic gonadotropin (β-HCG) during
• •4. Males capable of reproduction, defined as all men physiologically capable of producing sperm, including men whose career, lifestyle, or sexual orientation precludes intercourse with a female partner UNLESS the female partner meets the following definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels \>40 mIU/ml (IU/L) or the patient must agree to use two methods of birth control. This is any combination of hormonal contraception (implantable, patch ,oral or injection), IUD, male or female condom with spermicidal gel, diaphragm, sponge or cervical cap.
• •5. Patient is co-infected with HCV, HDV, or HIV.
• •6. Severe uncontrolled disease of other organ (heart, kidney, lung).
• •7. Patients who have previously been involved in a trial with telbivudine.
• •8. Patient has received nucleoside or nucleotide drugs whether approved or investigational at any time.
• •9. Patient has received IFN or other immunomodulatory treatment in the 6 months before Screening for this study.
• •10. Patient has a history of or clinical signs/symptoms of hepatic decompensation such as ascites, esophageal variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, hepatic hydrothorax, hepatopulmonary syndrome or spontaneous bacterial peritonitis, among others.
• •11. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir.
• •12. Patient has a history of malignancy of any organ system, treated or untreated, within the past 5 years whether or evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin. Patients with previous findings suggestive of possible hepatocellular carcinoma (HCC), should have the disease ruled out prior to entrance into the study.
• •14. History of any other acute or chronic medical condition that in the opinion of the investigator would make the patient unsuitable for inclusion into the study.
• •15. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.
• •16. Patient has a medical condition that requires frequent or prolonged use of systemic corticosteroids, although inhaled corticosteroids are allowed.
• •17. Patient has a history of clinical and laboratory evidence of chronic renal insufficiency (Estimated calculated serum creatinine clearance \< 50)
• •18. Patient has a medical condition requiring the chronic or prolonged use of potentially hepatotoxic drugs or nephrotoxic drugs.
• •19. Patient has any other concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study.
• •20. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
• •21. Patient has a history of myopathy, myositis, or persistent muscle weakness.
• •22. Patient has any of the following laboratory values during Screening:
• •* Hemoglobin \<11 g/dL (110 g/L) for men or \<10 g/dL (100 g/L) for women
• •* Total WBC \<3,500/mm3 (3.5 x 109/Liter)
• •* Absolute neutrophil count (ANC) \<1,500/mm3 (1.5 x 109/Liter)
• •* Platelet count \<75,000/mm3 (75 x 109/Liter)
• •* Serum amylases or lipase ≥ 1.5 x ULN
• •* Serum albumin \<3.3 g/dL (33g/L)
• •* Total bilirubin ≥ 2.0 mg/dL (34.2 μmol/L)
• •* Estimated calculated serum creatinine clearance \< 50 mL/min ( 0.48 ml/s) using the Cockcroft-Gault method with lean or ideal body weight; see Glossary of Terms (Cockcroft 1976)
• •* AFP \> 50 ng/mL or μg/L (requires further work up per local medical standards)
• •23. Patient has not fasted for 8 hours.
• •24. Patient has smoked on the day of the test.
• •25. Patient that has taken drugs that can interfere with methacetin metabolism: fluvoxamine, amiodarone, ciprofloxacin, cimetidine, rifampin, carbamazepine within the last 24 hours.
• •26. Patient has taken Tylenol or any other acetaminophen related medications within the past 24 hours.
• •27. Patients that received any new medication in the last 48 hours.
• •28. Patients that still suffer from any previous clinical intervention (e.g. biopsy)
• •29. Patients who have not consumed alcohol 24 hours prior the MBT or consume alcohol on a regular basis more than 40gr for male and 20gr for female per day.